Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 by Carolyn Helms | Feb 16, 2023 | Portfolio News
Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria by Carolyn Helms | Jan 30, 2023 | Portfolio News
Cohere Health Introduces Cohere Unify™ Intelligent Prior Authorization by Carolyn Helms | Jan 25, 2023 | Portfolio News
Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD) by Carolyn Helms | Jan 11, 2023 | Portfolio News
Orbus Therapeutics Enters Exclusive License Agreement for Intellectual Property Related to Treatment of Rare Pediatric Syndrome with Eflornithine by Carolyn Helms | Jan 10, 2023 | Portfolio News
